Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Assessing radiological response of IDH-mutated glioma to vorasidenib by tumor diameter slopes: a series of 8 cases.

Acta neurochirurgica - 3 Jun 2026

Mandonnet Emmanuel

Abstract excerpt

The INDIGO trial demonstrated improved progression-free survival under vorasidenib in IDH-mutated grade 2 glioma patients. However, the pattern of vorasidenib effects remains unknown. We thus performed a retrospective analysis of tumor kinetics in eight patients enrolled in the INDIGO trial. Tumor diameters (computed from FLAIR volumetry) and their slopes were individually estimated, before and under vorasidenib....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antineoplastic Agents
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Magnetic Resonance Imaging

Share to Mutation

Share to Triazines

Source

Open in PubMed Open full text

Identifiers

PMID: 42233993
DOI: 10.1007/s00701-026-06944-x
PMCID: PMC13427936

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Assessing radiological response of IDH-mutated glioma to vorasidenib by tumor diameter slopes: a series of 8 cases.PMID 42233993Read ↗

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade GliomaSemantic proximity Read ↗

Low-grade IDH -mutant gliomas: from standard post-surgical treatments to novel IDH inhibitorsSemantic proximity Read ↗

The Role of Mutant IDH Inhibitors in the Treatment of Glioma.Semantic proximity Read ↗

Advances in IDH-mutant glioma management: IDH inhibitors, clinical implications of INDIGO trial, and future perspectives.Semantic proximity Read ↗

Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial.Semantic proximity Read ↗

Glioma Response to IDH Inhibition: Real-World Experience.Semantic proximity Read ↗

18F-DOPA-PET and Advanced MRI Improve Treatment Response Assessment in IDH1/2-Mutant Gliomas Treated with IDH Inhibitors.Semantic proximity Read ↗

Vorasidenib: First Approval.Semantic proximity Read ↗

Targeted Options for Glioma Looking Good.Semantic proximity Read ↗

Evaluation of early metabolic changes following vorasidenib using FET PET in patients with IDH-mutant gliomasSemantic proximity Read ↗

Contemporary practice patterns in IDH-mutant glioma management: a multidisciplinary multi-institutional survey.Semantic proximity Read ↗

Amino acid PET imaging to monitor mIDH inhibitor treatments in patients with refractory IDH-mutant gliomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.